BridgeBio Pharma, Inc.
68.56USD
+0.4400 (+0.65%)
Fetching financial statements from SEC filings…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on BBIO.
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 244 | 195 | 154 | 121 | 111 | 117 | 6 | 3 |
| Cost of Revenue | 15 | 10 | 8 | 7 | 4 | 3 | 2 | 1 |
| Gross Profit | 229 | 185 | 146 | 114 | 107 | 114 | 4 | 2 |
| Operating Income | -107 | -106 | -140 | -145 | -134 | -104 | -226 | -192 |
| Net Income | -156 | -167 | -195 | -185 | -184 | -170 | -267 | -164 |
| EPS (Diluted) | -$0.78 | -$0.84 | -$0.99 | -$0.95 | -$0.95 | -$0.88 | -$1.42 | -$0.86 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)